全文获取类型
收费全文 | 2017篇 |
免费 | 163篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 59篇 |
妇产科学 | 39篇 |
基础医学 | 208篇 |
口腔科学 | 46篇 |
临床医学 | 641篇 |
内科学 | 324篇 |
皮肤病学 | 10篇 |
神经病学 | 112篇 |
特种医学 | 141篇 |
外科学 | 149篇 |
综合类 | 68篇 |
一般理论 | 1篇 |
预防医学 | 171篇 |
眼科学 | 8篇 |
药学 | 135篇 |
肿瘤学 | 103篇 |
出版年
2021年 | 19篇 |
2020年 | 12篇 |
2019年 | 18篇 |
2018年 | 39篇 |
2017年 | 22篇 |
2016年 | 21篇 |
2015年 | 24篇 |
2014年 | 38篇 |
2013年 | 76篇 |
2012年 | 64篇 |
2011年 | 49篇 |
2010年 | 55篇 |
2009年 | 58篇 |
2008年 | 61篇 |
2007年 | 68篇 |
2006年 | 62篇 |
2005年 | 56篇 |
2004年 | 69篇 |
2003年 | 44篇 |
2002年 | 67篇 |
2001年 | 64篇 |
2000年 | 62篇 |
1999年 | 64篇 |
1998年 | 111篇 |
1997年 | 105篇 |
1996年 | 86篇 |
1995年 | 72篇 |
1994年 | 62篇 |
1993年 | 62篇 |
1992年 | 43篇 |
1991年 | 43篇 |
1990年 | 45篇 |
1989年 | 43篇 |
1988年 | 46篇 |
1987年 | 28篇 |
1986年 | 23篇 |
1985年 | 38篇 |
1984年 | 22篇 |
1983年 | 13篇 |
1982年 | 16篇 |
1981年 | 15篇 |
1980年 | 13篇 |
1979年 | 26篇 |
1978年 | 15篇 |
1977年 | 14篇 |
1974年 | 10篇 |
1972年 | 19篇 |
1971年 | 14篇 |
1970年 | 9篇 |
1968年 | 12篇 |
排序方式: 共有2217条查询结果,搜索用时 15 毫秒
81.
82.
BACKGROUND: There is mounting evidence that low-intensity oral anticoagulation is effective, particularly in primary prevention of thrombosis, with important implications for safety and the practicalities of using warfarin. Because it is desirable to know possible benefits for different indications so that optimal therapy can be administered in as wide a range of conditions as possible, we analyzed data from the Thrombosis Prevention Trial, a factorial trial that compared treatment with low-intensity, dose-adjusted warfarin and low-dose aspirin separately and together, to determine the minimum effective intensity of oral anticoagulation in the primary prevention of coronary heart disease. METHODS: The international normalized ratio (INR) most recent to an event and overall time at each INR were used to calculate the INR-related event rate for coronary events, strokes, and major and minor bleeding episodes in 2545 men receiving warfarin with or without aspirin (75 mg/d) and followed up for a total of 9952 person-years. RESULTS: Compared with placebo, warfarin alone at a dose that maintained the INR at 1.4 or more significantly reduced the risk of a coronary event by 47% (95% confidence interval, 4%-70%; P =.03), whereas the risk of a coronary event was not reduced at INRs below 1. 4. Coronary events, strokes, and major bleeding episodes combined were significantly reduced by 45% (95% confidence interval, 9%-67%; P =.02) in the warfarin group compared with the placebo group when the INR was 1.4 or more. Minor bleeding episodes increased as the INR rose above about 2.0. No significant association of INR with coronary events was observed with combined warfarin and aspirin, possibly reflecting the small number of such events that occurred in this group, therefore limiting the power to detect an association with INR. CONCLUSIONS: Warfarin alone is effective in the primary prevention of coronary heart disease when the dose is adjusted to maintain an INR of 1.4 or more. The results add to the evidence that low-intensity, dose-adjusted oral anticoagulation is effective for a range of conditions. 相似文献
83.
Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood 总被引:48,自引:5,他引:48
Ingram DA Mead LE Tanaka H Meade V Fenoglio A Mortell K Pollok K Ferkowicz MJ Gilley D Yoder MC 《Blood》2004,104(9):2752-2760
Emerging evidence to support the use of endothelial progenitor cells (EPCs) for angiogenic therapies or as biomarkers to assess cardiovascular disease risk and progression is compelling. However, there is no uniform definition of an EPC, which makes interpretation of these studies difficult. Although hallmarks of stem and progenitor cells are their ability to proliferate and to give rise to functional progeny, EPCs are primarily defined by the expression of cell-surface antigens. Here, using adult peripheral and umbilical cord blood, we describe an approach that identifies a novel hierarchy of EPCs based on their clonogenic and proliferative potential, analogous to the hematopoietic cell system. In fact, some EPCs form replatable colonies when deposited at the single-cell level. Using this approach, we also identify a previously unrecognized population of EPCs in cord blood that can achieve at least 100 population doublings, replate into at least secondary and tertiary colonies, and retain high levels of telomerase activity. Thus, these studies describe a clonogenic method to define a hierarchy of EPCs based on their proliferative potential, and they identify a unique population of high proliferative potential-endothelial colony-forming cells (HPP-ECFCs) in human umbilical cord blood. 相似文献
84.
85.
86.
Prevention of lung cancer: The key is to stop smoking 总被引:1,自引:0,他引:1
MN RN CS ANPNancy L. Risser Adult Nurse Practitioner Primary Care 《Seminars in Oncology Nursing》1996,12(4):260-269
87.
88.
经肛门内镜显微手术切除直肠肿瘤 总被引:14,自引:3,他引:14
目的评价经肛门内镜显微手术(TEM)切除直肠绒毛状腺瘤和早期直肠癌的应用效果。方法分析我院总结1995年11月至2001年12月27例TEM手术的临床资料。结果本组患者肿瘤直径中位值2.5cm,肿瘤下缘与齿状线距离(8.9±3.4)cm,肿瘤侵犯直肠周径范围(35.7±17.5)%。平均手术时间(109±46)min。平均住院日4.5d。无围手术期死亡。手术并发症有尿潴留、暂时性大便失禁和慢性阻塞性肺病(COPD)复发。术中2例切穿至腹腔,即刻内镜下修补成功。切缘100%瘤细胞阴性。病理示直肠绒毛状腺瘤14例、直肠腺癌13例,后者包括pTis2例,pT16例和pT25例。直肠癌腔内超声肿瘤T分期符合率为84.6%。5例pT2中2例中转前切除术,1例接受术后放疗,2例无附加任何治疗。平均随访18个月,所有病例无局部复发。死亡2例,但无复发迹象。结论TEM易行且安全,是直肠绒毛状腺瘤和部分T1直肠癌的治愈性手术,也可作为T2直肠癌的姑息性治疗手段。 相似文献
89.
经肛门内镜显微手术治疗直肠绒毛状腺瘤和早期直肠癌31例 总被引:8,自引:1,他引:8
目的探讨经肛门内镜显微手术(transanal endoscopicmic rosurgery,TEM)治疗直肠绒毛状腺瘤和早期直肠癌的疗效。方法1995年11月~2003年12月,我院行TEM治疗直肠肿瘤31例。全麻下根据肿瘤位置选择合适的体位,经肛门插入特殊的手术直肠镜,保持CO2充气状态,在立体视镜和腔镜系统下,采用针形电刀或5mm超声刀将直肠肿瘤完整切除(黏膜下或全层切除),手术创口在腔内连续缝合。结果31例直肠肿瘤均获完整切除,切缘均阴性。手术时间45~220min,平均95min;术中出血量0~180ml,平均40ml。手术并发症:暂时性排气失控2例,急性尿潴留1例,慢性阻塞性气道疾病急性发作1例,因服用阿斯匹林而出现继发性出血1例。术后病理分期:pT0期16例,pTis期2例,pT1期7例,pT2和pT3期各3例。31例随访2~92个月,平均23个月,肿瘤无原位复发。结论TEM是治疗直肠绒毛状腺瘤和早期直肠癌的一种安全、有效的微创手术方法。 相似文献
90.
Kiluk JV Lee MC Park CK Meade T Minton S Harris E Kim J Laronga C 《The breast journal》2011,17(5):503-509
National Comprehensive Cancer Network (NCCN) guidelines for female breast cancer treatment and surveillance are well established, but similar guidelines on male breast cancers are less recognized. As an NCCN institution, our objective was to examine practice patterns and follow-up for male breast cancer compared to established guidelines for female patients. After Institutional Review Board approval, a prospective breast database from 1990 to 2009 was queried for male patients. Medical records were examined for clinico-pathological factors and follow-up. The 5-year survival rates with 95% confidence intervals were estimated using Kaplan-Meier method and Greenwood formula. Of the 19,084 patients in the database, 73 (0.4%) were male patients; 62 had complete data. One patient had bilateral synchronous breast cancer. The median age was 68.8 years (range 29-85 years). The mean/median invasive tumor size was 2.2/1.6 cm (range 0.0-10.0 cm). All cases had mastectomy (29 with axillary node dissection, 23 with sentinel lymph node biopsy only, 11 with sentinel node biopsy followed by completion axillary dissection). Lymph node involvement occurred in 25/63 (39.7%). Based on NCCN guidelines, chemotherapy, hormonal therapy, and radiation are indicated in 34 cases, 62 cases, and 14 cases, respectively. Only 20/34 (59%) received chemotherapy, 51/62 (82%) received hormonal therapy, and 10/14 (71%) received post-mastectomy radiation. Median follow-up was 26.2 months (range: 1.6-230.9 months). The 5-year survival estimates for node positive and negative diseases were 68.5% and 87.5%, respectively (p = 0.3). Despite the rarity of male breast cancer, treatment options based on current female breast tumors produce comparable results to female breast cancer. Increased awareness and a national registry for patients could help improve outcomes and tailor treatment recommendations to the male variant. 相似文献